WS #16355
Detailed data from the ESMO conference confirms that the Moderna and Merck therapeutic cancer vaccine (intismeran) met key endpoints in melanoma trials. This positive clinical data provides a rare bright spot in an otherwise risk-off environment, offering a potential catalyst for the biotech sector. The breakthrough underscores the continued progress in immuno-oncology, though its market impact is currently overshadowed by the broader macroeconomic and geopolitical headwinds.
Pharma & Biotech Breakthroughs
Detailed data from the ESMO conference confirms that the Moderna and Merck therapeutic cancer vaccine (intismeran) met key endpoints in melanoma trials. This positive clinical data provides a rare bright spot in an otherwise risk-off environment, offering a potential catalyst for the biotech sector. The breakthrough underscores the continued progress in immuno-oncology, though its market impact is currently overshadowed by the broader macroeconomic and geopolitical headwinds.